Houyau Philippe

Oncologie médicale

Hôpital Jacques Puel - Bourran
Rodez, France

26 Activités

0 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Métastase tumorale Tumeurs colorectales Adénocarcinome Tumeurs du pancréas Leucémies Cellules tumorales circulantes Tumeurs du foie Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde

Collaborateurs

Berge Yann

Hôpital Jacques Puel - Bourran, Rodez, France

Bouche Olivier

Hôpital Robert-Debré Reims, Reims, France

Francois Eric

Centre Antoine Lacassagne, Nice, France

Bernard Pascale

Cl De L'union Saint Jean, Saint-Jean, France

Industries

MSD

5 collaboration(s)

Dernière en 2023

AstraZeneca

4 collaboration(s)

Dernière en 2022

Ipsen

1 collaboration(s)

Dernière en 2021

Pfizer

1 collaboration(s)

Dernière en 2020

Dernières activités

ADAGE: Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi

Essai Clinique (Fédération Francophone de Cancérologie Digestive) 16 août 2023

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab: Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Essai Clinique (Unicancer) 07 janvier 2022

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

British journal of cancer 06 janvier 2022

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases: Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases

Essai Clinique (Unicancer) 14 juin 2021

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

2018 ASCO Annual Meeting I 01 juin 2018

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

2018 ASCO Annual Meeting I 01 juin 2018

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

2016 ASCO Annual Meeting I 20 mai 2016

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.

European journal of haematology 17 septembre 2014

Houyau Philippe

Oncologie médicale

Hôpital Jacques Puel - BourranRodez, France

Production scientifique

Activités par an

Expertise

Sujets de recherche

Collaborateurs

Industries

Dernières activités

Hôpital Jacques Puel - Bourran
Rodez, France